BridgeMD
New treatment option for Post-Concussion Syndrome
Official title Interest of the 7 Tesla MRI in the Diagnosis of Post-concussion Syndromes Among Patients With Mild Traumatic Brain Injury
ClinicalTrials.gov ID: NCT04982562
What this study is testing
- What it's testing
- We aimed to conduct a prospective longitudinal interventionnal monocentric study to assess the ability of seven tesla MRI to detect diffuses axonal lesions in patients presenting a post concussional syndrom (PCS) at seven days about a mild traumatic brain injury (MTBI). Our first objective was to evaluate the diagnostic performance of seven tesla MRI runned at seven days after MTBI among patients presenting a PCS.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 72
You may be able to join if
- Mild traumatic brain injury with glascow included between 13 and 15, with indication of scan
- possibilty of performing an MRI at 7 days
- Patient able to get to MRI at Day 7
- Free consentement to the study
- Any measure of guardianship or curatorship , any link of subordination
You likely can't join if
- Patient does not hospitalized about head trauma
- Inhability to move out for run the seven day MRI
- Contraindication for MRI
- Patient having already consulted the emergency for head trauma requiring imaging
- Patients with psychiatric troubles : bipolarity, panic trouble, depressive trouble, schizophrenia
- Patient already enrolled in the study
See the full eligibility criteria
- Mild traumatic brain injury with glascow included between 13 and 15, with indication of scan
- possibilty of performing an MRI at 7 days
- Patient able to get to MRI at Day 7
- Free consentement to the study
- Any measure of guardianship or curatorship , any link of subordination
- Patient does not hospitalized about head trauma
- Inhability to move out for run the seven day MRI
- Contraindication for MRI
- Patient having already consulted the emergency for head trauma requiring imaging
- Patients with psychiatric troubles : bipolarity, panic trouble, depressive trouble, schizophrenia
- Patient already enrolled in the study
- History of brain, tumor or neurosurgery
- Untreated or poorly treated chronic vertigo
- Untreated or poorly treated chronic migraines
- Claustrophobia
- BMI \> 40
- Refusal of consent to take part of the study
- No social welfare or inhability to benefit of it by a third party
- Patients with enhanced protection : minor aged under 18 ; person with freedom restriction by justice decision or administrative ; homeliving in health or social establishment ; adult in legal protection
- Pregnant and nursing women
The study team makes the final eligibility decision.
Where it's taking place
- Poitiers, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 72 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poitiers, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.